'Hook'ed on KRAS, Roche lines up li­cens­ing deal as it pur­sues Mi­rati and Am­gen

Be­hind Am­gen and Mi­rati are a whole host of play­ers lin­ing up their own KRAS can­di­dates.

Roche is no ex­cep­tion. The Big Phar­ma al­ready has its own in-house KRAS drug from its sub­sidiary Genen­tech that is cur­rent­ly in Phase I stud­ies, but is now ex­pand­ing its op­tions.

Roche has li­censed a pre­clin­i­cal KRAS pro­gram from Hookipa Phar­ma for $25 mil­lion up­front, Hookipa an­nounced Thurs­day morn­ing. Roche al­so has the op­tion of adding a sec­ond im­munother­a­py can­di­date for $15 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER